Biopsy tolerance study ends early – what we know

NCT ID NCT05022420

Terminated Knowledge-focused Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to understand how well patients tolerate biopsies for autoimmune diseases and whether they feel properly informed. It planned to enroll 505 people but was terminated early. The results may help improve patient experience with these common procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOPSY SITE ITCHING TOLERANCE

Contacts and locations

Locations

CH de Quimper

Quimper, 20007, France
CHRU de Brest

Brest, 29609, France
CHU d'ANGERS

Angers, France
CHU de Bordeaux

Bordeaux, 33000, France
CHU de LILLE

Lille, 59037, France
CHU de Marseille

Marseille, France
CHU de Tours

Tours, France
Hôpital de la Salpétrière

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.